In two prospective, randomized multicenter double-blind studies with a dosage of either 250 mg given four times a day (study A) or 500 mg given two times a day (study B), the comparative efficacy and safety of cephalexin hydrochloride (LY061188; Keftab) and cephalexin monohydrate (Keflex) for treatment of skin and soft tissue infections were determined. In study A, 97 patients received cephalexin hydrochloride and 101 patients received cephalexin monohydrate. In study B, 75 patients received cephalexin hydrochloride and 70 patients received cephalexin monohydrate. Diagnoses included abscesses, ceilulitis, wound infections, and infected dermatitis, and were comparable in the different treatment groups. Pathogens were isolated from 82% of patients enrolled; the majority of isolates were of Staphylococcus aureus, Streptococcus pyogenes, other staphylococcal species, and a few gram-negative bacteria. In study A, 68 of 71 (95.7%) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 73 of 81 (90%) patients who received cephalexin monohydrate also responded satisfactorily. In study B, 56 of 58 (96.5%) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 47 of 50 (94%) patients who received cephalexin monohydrate also responded satisfactorily. An adverse clinical event leading to discontinuation of the treatment drug developed in 17 of 343 (4.95%) patients in both studies. No differences were noted between the two drugs. Skin eruptions, pruritis, and mild gastrointestinal symptoms were the common adverse effects. These data suggest that cephalexin hydrochloride, a new formulation of cephalexin, is a safe and effective antimicrobial agent for treatment of a variety of skin and subcutaneous infections in a dosage of either 250 mg four times a day or 500 mg twice a day.
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Cephalexin hydrochloride (LY061188, Keftab; Eli Lilly & Co., Indianapolis, Ind.) is a new formulation of cephalexin monohydrate (Keflex; Eli Lilly & Co.). In limited pharmacokinetic studies, cephalexin hydrochloride is bioequivalent with cephalexin monohydrate (data on file; Eli Lilly & Co.). In bioavailability studies with 16 fasting human volunteers, concentrations of cephalexin hydrochloride in serum (13.3 ± 13.9 and 18.9 ± 6.8 ,ug/ml) were significantly greater than those of cephalexin monohydrate (0.2 ± 0.5 and 11.9 ± 8.7 jig/ml) at 15 and 30 min, respectively, after the oral dose (data on file; Eli Lilly & Co.). The differences in the area under the curve and peak drug concentrations in serum were not statistically significant. At 120 and 180 min, the differences were not significant between the drug concentrations in serum (cephalexin hydrochloride, 5.8 ± 2.4 and 2.0 ± 0.3, respectively; cephalexin monohydrate, 6.8 ± 4.4 and 2.4 ± 1.0, respectively). Similarly, the urinary excretions of both drugs were comparable. It is believed that the rapid absorption of the hydrochloride is due to the fact that cephalexin hydrochloride is immediately available for absorption, while the cephalexin monohydrate must first be converted to cephalexin hydrochloride in the stomach by gastric acid. To determine if rapid absorption of cephalexin hydrochloride offers any possible therapeutic advantage or disadvantage, as compared with cephalexin monohydrate, clinical studies were undertaken to compare the efficacy and safety of these two compounds of cephalexin in the treatment of skin and soft tissue infections in two double-blind protocols.
(Part of this research was presented at the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, N.Y., 4 to 7 October 1987.)
MATERIALS AND METHODS
In multicenter trials, the safety and efficacy of cephalexin hydrochloride were compared with those of cephalexin monohydrate in the treatment of skin infections, by using two protocols. These protocols were identical in design and other requirements, except that in the first protocol (study A), patients were given 250 mg of drug four times a day, while in the second protocol (study B), a 500-mg dose was administered twice a day. In these multicenter studies, patients fulfilling all of the following criteria were enrolled: (i) patients presenting with signs and symptoms of a skin infection in an outpatient setting; (ii) patients who were generally in good health (except for the skin infection) and in 
3) 1 (1.0) a In study A, 97 patients were given cephalexin hydrochloride and 101 patients were given cephalexin monohydrate; in study B, 75 patients were given cephalexin hydrochloride and 70 patients were given cephalexin monohydrate.
whom an oral cephalosporin would be an appropriate therapy for a skin infection; (iii) patients weighing more than 44 lb (1 lb = 453.592 g) and able to swallow tablets or capsules; and (iv) patients having predominantly pathogenic organisms isolated from the culture obtained on the initial visit that were susceptible to cephalothin. Patients who were suspected of renal or hepatic impairment, who had known hypersensitivity to penicillins or cephalosporins, or who were suffering from a significant underlying disease or condition, which in the opinion of the investigator could preclude evaluation of response, were not enrolled in the study. Pregnancy was also an exclusion criterion. Informed consent was obtained from each patient. If the patient was a minor, consent from a parent or guardian was obtained.
After the initial examination, pretreatment laboratory studies (complete blood count, liver enzymes, blood urea nitrogen, creatinine, bilirubin, alkaline phosphatase, urine analysis, and direct Coombs test) were obtained. Depending on the nature of the soft tissue infection, a swab from the base of the lesion or an aspirate from the lesion after appropriate skin cleansing was obtained for bacterial culture. Patients enrolled in the study were assigned sequential numbers, and a corresponding package of the drug was given to the patient. Physicians were kept uninformed as to the contents of coded samples. Patients were instructed regarding the frequency of dosage administration. Patients were further instructed to keep a record of any new symptoms appearing during the treatment, and they were to contact the treating physician immediately should symptoms appear. Patients were rechecked (follow-up visit) between days 7 (the last day of the treatment) and 14. Patients were assessed for symptomatic response to treatment and for any evidence of adverse effects. Response to treatment was considered satisfactory if: (i) symptoms of illness resolved; (ii) the lesion(s) healed completely; and (iii) in the judgment of the treating physician, the patient did not need any more systemic or local antimicrobial treatment. Response was considered unsatisfactory if any of the above three criteria were not met when patient was rechecked on the follow-up visit. If the lesion had not healed (unsatisfactory response), then pus or other appropriate material from the lesion was obtained for a repeat bacterial culture. Patients were also required to return the unused medication to the physician. Returned medication was counted as a compliance check, and the count was noted in the case report form. During the follow-up visit, laboratory tests (complete blood count, liver enzymes, blood urea nitrogen, creatinine, bilirubin, alkaline phosphatase, urine analysis, and direct Coombs test) were also repeated to determine any posttreatment abnormalities. A case report form was completed on each patient. Study patients were not permitted to take other antimicrobial agents during the study. Any other medications taken during the study were recorded on the case report form. Bacterial isolates from the patients were further identified by using standard biochemical and other laboratory tests. Antibiotic susceptibility patterns for these isolates were determined (either MICs or disk zone inhibition [1] ).
At the end of the study, patients were grouped according to the treatment received and data were analyzed.
RESULTS
Data for both study A (250-mg dose four times a day) and study B (500-mg dose twice a day) were analyzed for clinical diagnoses, pathogens were isolated, and symptomatic response, adverse effects, and abnormal laboratory values were obtained. Study A. A total of 198 patients were enrolled; 97 received cephalexin hydrochloride, and 101 received cephalexin monohydrate for skin infections. For patients who received cephalexin hydrochloride, the mean age was 34.7 + 23.8 years; 52 were female, and 45 were male. For patients who received cephalexin monohydrate, the mean age was 38.8 ± 22.6 years; 58 were female, and 43 were male. Heights and weights were almost identical in both treatment groups. The diagnoses in both groups of patients included subcutaneous abscesses, cellulitis, wound infections, skin ulcers, infected dermatitis (folliculitis, impetigo pustules, and infected eczema), paronychia, and others (Table 1) . A total of 4 of 97 (4.1%) patients who received cephalexin hydrochloride and 7 of 101 patients (6.9%) who received cephalexin monohydrate had failed prior treatment for their infections.
Pathogens isolated from these patients are shown in Table  2 . In 13 of 97 patients who received cephalexin hydrochloride and in 16 of 101 patients who received cephalexin monohydrate, no pathogen could be isolated. Over 89% (151 of 169) of isolates were either species of staphylococcus or streptococcus, the majority of them being Staphylococcus aureus. Of 71 evaluable patients who received cephalexin hydrochloride and from whom a pathogen was isolated, 68 (95.7%) responded satisfactorily (resolution of the infection).
Of 81 evaluable patients who received cephalexin monohydrate and from whom a pathogen was isolated, 73 (90%) also responded satisfactorily. Of 71 evaluable patients who re-VOL. 32, 1988 [4.6%] ). In the cephalexin tion, whereas one patient in the cephalexin monohydrate monohydrate treatment group, skin eruptions and/or pruritis treatment group had failed prior therapy for the infection. were observed in three patients, gastrointestinal symptoms Pathogens isolated from skin and soft tissue lesions are were observed in two patients, and malaise was observed in shown in Table 3 . For 17 of 75 patients (22.6%) who received one patient. Three adverse effects (chills and fever, convulcephalexin hydrochloride and 15 of 70 patients (21.4%) who sions, and congestive heart failure) were observed in a received cephalexin monohydrate, no pathogen could be 78-year-old male who presented with cellulitis of the right isolated. Over 98% (111 of 113) of organisms isolated were leg. This patient had various other problems (peripheral either staphylococcus or streptococcus species, the majority vascular disease, thrombosis of lower extremities, aortic being S. aureus. Of 58 patients who received cephalexin stenosis, seizure disorder, chronic obstructive pulmonary hydrochloride and from whom a pathogen was isolated, 56 disease, organic brain syndrome, and status postsurgery on (96.5%) responded satisfactorily (resolution of symptoms). great vessels), and he was also treated approximately 6 weeks earlier for a cellulitis on his other leg with cephalexin monohydrate (outside the study). The patient presented with cellulitis on an area of venous insufficiency and was enrolled in the study. The patient took a total of three doses of the drug when he suddenly worsened and was brought to the emergency room with congestive heart failure and gramnegative bacterial sepsis. Despite supportive treatment, he expired 13 days later. This patient also had an elevated baseline serum creatinine value (2.8 mg/100 ml).
In the cephalexin hydrochloride treatment group, skin eruptions and/or pruritis were observed in three patients, gastrointestinal symptoms were observed in two patients, and pharyngitis, myocardial infarction, and increased creatinine were observed in one patient each. Myocardial infarction occurred in a 39-year-old male smoker with a history of two previous myocardial infarctions and elevated cholesterol and triglycerides, who presented with an abdominal wall cellulitis. The patient was enrolled in the study at noon in the office of the physician. The same evening after his meal, the patient developed chest pain and then had a cardiac arrest. All attempts to resuscitate him failed. Cultures obtained from an area of cellulitis eventually grew Staphylococcus epidermidis. The patient had taken only 2 tablets of cephalexin hydrochloride before this event. The last dose of cephalexin hydrochloride was taken 2 h before the event. There was no evidence of hives, erythema, or airway obstruction or any other evidence to suggest anaphylactic shock.
DISCUSSION
In this multicenter study of skin and soft tissue infections, the etiological agents included a variety of gram-positive cocci, with a few gram-negative bacteria, and there was a wide spectrum of clinical diagnoses. The types of bacteria observed here are similar to those reported in several studies, which were summarized by Blumer et al. (2) and Pankey et al. (9) . Therapy with cephalexin hydrochloride, a rapidly absorbable formulation of cephalexin, proved comparable with the treatment with cephalexin monohydrate, which has been used for over 17 years, in both studies. In study A, in which a 250-mg dose was administered four times a day, 68 of 71 (over 95%) evaluable patients had a satisfactory response. In the same study, 73 of 81 (90%) evaluable patients had a satisfactory response with cephalexin monohydrate. The types of organisms and diagnoses of lesions were comparable for both groups. Similarly, in study B, in which a 500-mg dose was administered twice a day, cephalexin hydrochloride treatment resulted in a satisfactory response in 56 of 58 (96.5%) evaluable patients, as compared with a satisfactory response in 47 of 50 (94%) evaluable patients who received cephalexin monohydrate. Clinical diagnoses and etiological pathogens were also comparable in patients enrolled in study B. Cure rates achieved by either of the drugs used in this study are comparable with those reported in other studies of skin and soft tissue infections (3) (4) (5) (6) 9) .
Both agents were well tolerated. A clinical event leading to discontinuation of the study drug occurred in less than 5% (17 of 343) of patients in both studies. No differences were noted in patients who received either cephalexin hydrochlo-ride or cephalexin monohydrate. Two patients (one who received cephalexin hydrochloride and one who received cephalexin monohydrate) developed fatal illnesses. Death in neither of these two cases was felt to be secondary to the study drug, since both patients had other underlying medical illnesses contributing to the fatality. Mild, self-limiting skin eruptions and gastrointestinal symptoms (abdominal pain, nausea, and vomiting) were the common adverse effects observed. None of the patients developed a serum sicknesslike illness, erythema multiforme, or urticarial lesions, which have been reported in some patients treated with another cephalosporin (8) . The therapeutic efficacy and adverse effects of several antibacterial agents, valuable for treatment of skin and subcutaneous infections, were reviewed recently (2, 7, 10) .
The results of this study suggest that cephalexin hydrochloride, a rapidly absorbable new formulation of cephalexin monohydrate, is also a safe and effective antimicrobial agent for treatment of a variety of skin and subcutaneous infections in dosages of either 250 mg four times a day or 500 mg twice a day. Twice-a-day dosages were well tolerated and definitely had an advantage as far as the compliance of patients is concerned.
